



|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
|  <b>SUPPLEMENTAL INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br>James McSwiggen           |                                 |
|   |  | <b>Filing Date:</b><br>February 20, 2004       | <b>Group:</b><br>1614           |

## U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initial |   | Document Number | Filing Date | Name             | Class | Subclass | Publication Date If Appropriate |
|------------------|---|-----------------|-------------|------------------|-------|----------|---------------------------------|
| KC               | * | US 2003/0190635 | 10/2003     | McSwiggen et al. |       |          |                                 |
| KC               | * | US 2003/0206887 | 11/2003     | Morrissey et al. |       |          |                                 |

## FOREIGN PATENT DOCUMENTS

|    |     | Document Number | Date     | Country                   | Class | Subclass | Translation |    |
|----|-----|-----------------|----------|---------------------------|-------|----------|-------------|----|
|    |     |                 |          |                           |       |          | Yes         | No |
| KC | 1.  | 1325955         | 07/09/03 | EP (Klippel-Giese et al.) |       |          |             |    |
|    | 14. | 08208687        | 08/1996  | JP (Hotoda et al.)        |       |          |             |    |
|    | 2.  | 95/04142        | 02/09/95 | WO (Robinson)             |       |          |             |    |
|    | 3.  | 01/097850       | 12/27/01 | WO (Siemeister et al.)    |       |          |             |    |
|    | 4.  | 02/07747        | 01/31/02 | WO (King)                 |       |          |             |    |
|    | 5.  | 02/10378        | 02/07/02 | WO (Cowser et al.)        |       |          |             |    |
|    | 6.  | 02/096927       | 12/05/02 | WO (Escobedo et al.)      |       |          |             |    |
|    | 7.  | 03/068797       | 08/21/03 | WO (Rossi et al.)         |       |          |             |    |
| ✓  | 8.  | 03/070910       | 08/28/03 | WO (McSwiggen et al.)     |       |          |             |    |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|  |  |                                   |            |
|--|--|-----------------------------------|------------|
| FORM PTO-1449<br>(Rev. 2-32)   | U.S. Department of Commerce<br>Patent and Trademark Office | Atty. Docket No.                  | Serial No. |
| SUPPLEMENTAL INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br><br>(Use several sheets if necessary) |  | 04-105<br>(400/146)               | 10/783,128 |
|  |  | Applicant:<br><br>James McSwiggen |            |
|  |  | Filing Date:                      | Group:     |
|  |  | February 20, 2004                 | 1614       |


|    |     |           |          |                     |  |  |  |  |
|----|-----|-----------|----------|---------------------|--|--|--|--|
| KC | 9.  | 03/080638 | 10/02/03 | WO (Lacasse et al.) |  |  |  |  |
| ↓  | 10. | 04/043977 | 05/27/04 | WO (Prakush et al.) |  |  |  |  |
| ↓  | 16. | 04/047872 | 06/10/04 | WO (Kaemmerer)      |  |  |  |  |
| ↓  | 11. | 04/072261 | 08/26/04 | WO (Li et al.)      |  |  |  |  |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

|    |     |  |
|----|-----|--|
| KC | 12. | Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," Oligonucleotides, 13:303-312 (2003)                   |
| ↓  | 15. | Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglycerol derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984) |
| ↓  | 13. | International Search Report for PCT/US2004/016390 mailed March 31, 2005  |

|          |   |                 |        |
|----------|---|-----------------|--------|
| EXAMINER |  | DATE CONSIDERED | 8/3/05 |
|----------|---|-----------------|--------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


|  |  |  |   |                              |
|--|--|--|---|------------------------------|
| FORM PTO-1449<br>(Rev. 2-32)   |  | U.S. Department of Commerce<br>Patent and Trademark Office | Atty. Docket No.<br><br>MBHB04-105<br>(400/146) | Serial No.<br><br>10/783,128 |
| SUPPLEMENTAL INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br><br>(Use several sheets if necessary) |  |  | Applicant:<br>McSwiggen et al.                  |                              |
|  |  |  | Filing Date:<br>February 20, 2004               | Group:<br>1614               |

## FOREIGN PATENT DOCUMENTS

|    |    | Document Number | Date     | Country               | Class | Subclass | Translation |    |
|----|----|-----------------|----------|-----------------------|-------|----------|-------------|----|
|    |    |                 |          |                       |       |          | Yes         | No |
| KC | 1. | WO 2004/047872  | 06/10/04 | WO (Kaemmerer et al.) |       |          |             |    |
|    |    |                 |          |                       |       |          |             |    |


|                           |                               |
|---------------------------|-------------------------------|
| EXAMINER <i>Kberf Chg</i> | DATE CONSIDERED <i>8/3/05</i> |
|---------------------------|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen /         |                                     |
|                        |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

### U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initial |   | Document Number | Filing Date | Name                  | Class | Subclass | Publication Date if Appropriate |
|------------------|---|-----------------|-------------|-----------------------|-------|----------|---------------------------------|
| KC               | * | 09/301,511      | 04/28/99    | Beigleman et al.      |       |          |                                 |
|                  | * | 09/740,332      | 12/18/00    | Blatt et al.          |       |          |                                 |
|                  | * | 09/800,594      | 03/06/01    | Usman and McSwiggen   |       |          |                                 |
|                  | * | 10/151,116      | 05/17/02    | Matulic-Adamic et al. |       |          |                                 |
|                  | * | 10/201,394      | 08/13/01    | Vargeese et al.       |       |          |                                 |
|                  | * | 10/417,012      | 04/16/03    | McSwiggen et al.      |       |          |                                 |
|                  | * | 10/422,704      | 04/24/03    | McSwiggen et al.      |       |          |                                 |
|                  | * | 10/427,160      | 04/30/03    | Vargeese et al.       |       |          |                                 |
|                  | * | 10/444,853      | 05/23/03    | McSwiggen et al.      |       |          |                                 |
|                  | * | 10/652,791      | 08/29/03    | McSwiggen et al.      |       |          |                                 |
|                  | * | 10/693,059      | 10/23/03    | McSwiggen et al.      |       |          |                                 |
|                  | * | 10/720,448      | 11/24/03    | McSwiggen et al.      |       |          |                                 |
|                  | * | 10/727,780      | 12/03/03    | Vaish et al.          |       |          |                                 |
|                  | * | 10/757,803      | 01/14/04    | McSwiggen et al.      |       |          |                                 |
|                  | * | 60/082,404      | 04/20/98    | Thompson et al.       |       |          |                                 |
|                  | * | 60/292,217      | 05/18/01    | Adamic et al.         |       |          |                                 |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b><br><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
|   |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |   |                 |          |                       |  |  |          |
|----|---|-----------------|----------|-----------------------|--|--|----------|
| KC | * | 60/306,883      | 07/20/01 | Vargeese et al.       |  |  |          |
|    | * | 60/311,865      | 08/13/01 | Vargeese et al.       |  |  |          |
|    | * | 60/358,580      | 02/20/02 | Beigelman et al.      |  |  |          |
|    | * | 60/362,016      | 03/06/02 | Matulic-Adamic et al. |  |  |          |
|    | * | 60/363,124      | 03/11/02 | Beigelman et al.      |  |  |          |
|    | * | 60/386,782      | 06/06/02 | Beigelman et al.      |  |  |          |
|    | * | 60/402,996      | 08/13/02 | Usman et al.          |  |  |          |
|    | * | 60/406,784      | 08/29/02 | Beigelman et al.      |  |  |          |
|    | * | 60/408,378      | 09/05/02 | Beigelman et al.      |  |  |          |
|    | * | 60/409,293      | 09/09/02 | Beigelman et al.      |  |  |          |
|    | * | 60/440,129      | 01/15/03 | Beigelman et al.      |  |  |          |
|    | * | 60/543,480      | 02/10/04 | Jadhavi et al.        |  |  |          |
|    | * | US 2001/0007666 | 01/05/99 | Hoffman et al.        |  |  | 07/12/01 |
|    | * | US 2002/0130430 | 12/29/00 | Caster                |  |  | 09/19/02 |

## U.S. PATENT DOCUMENTS


| Examiner Initial |   | Document Number | Date     | Name        | Class | Subclass | Filing Date if Appropriate |
|------------------|---|-----------------|----------|-------------|-------|----------|----------------------------|
| KC               | * | 4,987,071       | 01/22/91 | Cech et al. |       |          |                            |

|                         |                               |
|-------------------------|-------------------------------|
| EXAMINER <i>K. Berg</i> | DATE CONSIDERED <i>8/3/05</i> |
|-------------------------|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |                                     |
|---|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b><br><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
|   | <b>Applicant:</b><br><br>James McSwigger           |                                     |
|   | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |   |           |          |                  |  |  |  |
|----|---|-----------|----------|------------------|--|--|--|
| KC | * | 5,108,921 | 04/28/92 | Low et al.       |  |  |  |
|    | * | 5,138,045 | 08/11/92 | Cook et al.      |  |  |  |
|    | * | 5,214,136 | 05/25/93 | Lin et al.       |  |  |  |
|    | * | 5,334,711 | 08/02/94 | Sproat           |  |  |  |
|    | * | 5,416,016 | 05/16/95 | Low et al.       |  |  |  |
|    | * | 5,589,332 | 12/31/96 | Shih et al.      |  |  |  |
|    | * | 5,624,803 | 04/29/97 | Noonberg et al.  |  |  |  |
|    | * | 5,627,053 | 05/06/97 | Usman et al.     |  |  |  |
|    | * | 5,631,359 | 05/20/97 | Chowrira et al.  |  |  |  |
|    | * | 5,631,360 | 05/20/97 | Usman et al.     |  |  |  |
|    | * | 5,633,133 | 05/27/97 | Long et al.      |  |  |  |
|    | * | 5,670,633 | 09/23/97 | Cook et al.      |  |  |  |
|    | * | 5,672,695 | 09/30/97 | Eckstein et al.  |  |  |  |
|    | * | 5,716,824 | 02/10/98 | Beigelman et al. |  |  |  |
|    | * | 5,741,679 | 04/21/98 | George et al.    |  |  |  |
|    | * | 5,792,847 | 08/11/98 | Buhr et al.      |  |  |  |
|    | * | 5,804,683 | 09/08/98 | Usman et al.     |  |  |  |
|    | * | 5,814,620 | 09/29/98 | Robinson et al.  |  |  |  |
| ↓  | * | 5,831,071 | 11/03/98 | Usman et al.     |  |  |  |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-105  
(400/146)

Serial No.

10/783,128

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

James McSwiggen

Filing Date:

February 20, 2004

Group:

|    |   |           |          |                  |  |  |  |
|----|---|-----------|----------|------------------|--|--|--|
| KE | * | 5,834,186 | 11/10/98 | George et al.    |  |  |  |
|    | * | 5,849,902 | 12/15/98 | Arrow et al.     |  |  |  |
|    | * | 5,854,038 | 12/29/98 | Sullenger et al. |  |  |  |
|    | * | 5,871,914 | 02/16/99 | Nathan et al.    |  |  |  |
|    | * | 5,889,136 | 03/30/99 | Scaringe et al.  |  |  |  |
|    | * | 5,898,031 | 04/27/99 | Crooke           |  |  |  |
|    | * | 5,902,880 | 05/11/99 | Thompson et al.  |  |  |  |
|    | * | 5,989,912 | 11/23/99 | Arrow et al.     |  |  |  |
|    | * | 5,998,203 | 12/07/99 | Adamic et al.    |  |  |  |
|    | * | 6,001,311 | 12/14/99 | Brennan          |  |  |  |
|    | * | 6,005,087 | 12/21/99 | Cook et al.      |  |  |  |
|    | * | 6,008,400 | 12/28/99 | Scaringe et al.  |  |  |  |
|    | * | 6,054,576 | 04/25/00 | Bellon et al.    |  |  |  |
|    | * | 6,107,094 | 08/22/00 | Crooke           |  |  |  |
|    | * | 6,111,086 | 08/29/00 | Scaringe et al.  |  |  |  |
|    | * | 6,117,657 | 09/12/00 | Usman et al.     |  |  |  |
|    | * | 6,146,886 | 06/12/01 | Thompson et al.  |  |  |  |
|    | * | 6,153,737 | 11/28/00 | Manoharan et al. |  |  |  |
| ✓  | * | 6,162,909 | 12/19/00 | Bellon et al.    |  |  |  |

EXAMINER

*Kberg Cle*


DATE CONSIDERED

8/3/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |                                     |
|---|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b><br><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
|   | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |   |           |          |                  |  |  |  |
|----|---|-----------|----------|------------------|--|--|--|
| KE | * | 6,168,778 | 01/02/01 | Janjic et al.    |  |  |  |
|    | * | 6,180,613 | 01/30/01 | Kaplitt et al.   |  |  |  |
|    | * | 6,235,310 | 05/22/01 | Wang et al.      |  |  |  |
|    | * | 6,235,886 | 05/22/01 | Manoharan et al. |  |  |  |
|    | * | 6,248,878 | 06/19/01 | Adamic et al.    |  |  |  |
|    | * | 6,300,074 | 10/09/01 | Gold             |  |  |  |
|    | * | 6,303,773 | 10/16/01 | Bellon et al.    |  |  |  |
|    | * | 6,335,434 | 01/01/02 | Guzaev et al.    |  |  |  |
|    | * | 6,353,098 | 03/05/02 | Usman et al.     |  |  |  |
|    | * | 6,362,323 | 03/26/02 | Usman et al.     |  |  |  |
|    | * | 6,395,492 | 05/28/02 | Manoharan et al. |  |  |  |
|    | * | 6,395,713 | 05/28/02 | Beigelman et al. |  |  |  |
|    | * | 6,437,117 | 08/20/02 | Usman et al.     |  |  |  |
|    | * | 6,447,796 | 09/10/02 | Vook et al.      |  |  |  |
|    | * | 6,469,158 | 10/22/02 | Usman et al.     |  |  |  |
|    | * | 6,476,205 | 11/05/02 | Buhr et al.      |  |  |  |
|    | * | 6,506,559 | 06/14/03 | Fire et al.      |  |  |  |
|    | * | 6,528,631 | 03/04/03 | Cook et al.      |  |  |  |
|    | * | 6,586,524 | 07/01/03 | Sagara           |  |  |  |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |             |          |                       |  |  |  |
|----|-------------|----------|-----------------------|--|--|--|
| KC | • 6,617,156 | 09/09/03 | Doucette-Stamm et al. |  |  |  |
|----|-------------|----------|-----------------------|--|--|--|

## FOREIGN PATENT DOCUMENTS


|    |   | Document Number                              | Date     | Country               | Class | Subclass | Translation |    |
|----|---|--|----------|-----------------------|-------|----------|-------------|----|
|    |   |  |          |                       |       |          | Yes         | No |
| KC | • | 2001240375<br>(Old Application No. 40375/01) | 03/16/01 | AU (Graham et al.)    |       |          |             |    |
|    | • | 2,359,180                                    | 08/03/00 | CA (Kreutzer et al.)  |       |          |             |    |
|    | • | 0 360 257                                    | 02/28/90 | EP (Hampel et al.)    |       |          |             |    |
|    | • | 1144623 B1                                   | 01/29/02 | EP (Kreutzer et al.)  |       |          |             |    |
|    | • | 88/09810                                     | 12/15/88 | WO (Tullis et al.)    |       |          |             |    |
|    | • | 89/02439                                     | 03/23/89 | WO (Arnold et al.)    |       |          |             |    |
|    | • | 90/12096                                     | 10/18/90 | WO (Low et al.)       |       |          |             |    |
|    | • | 90/14090                                     | 11/29/90 | WO (Gillespie et al.) |       |          |             |    |
|    | • | 91/03162                                     | 03/21/91 | WO (Rossi et al.)     |       |          |             |    |
|    | • | 92/07065                                     | 04/30/92 | WO (Eckstein et al.)  |       |          |             |    |
|    | • | 93/15187                                     | 08/05/93 | WO (Usman et al.)     |       |          |             |    |
|    | • | 93/23569                                     | 11/25/93 | WO (Draper et al.)    |       |          |             |    |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br>February 20, 2004       | <b>Group:</b>                   |


|    |    |            |          |                                    |  |  |  |  |
|----|----|------------|----------|------------------------------------|--|--|--|--|
| KE | *  | 94/01550   | 01/20/94 | WO (Agrawal et al.)                |  |  |  |  |
|    | *  | 94/02595   | 02/03/94 | WO (Sullivan et al.)               |  |  |  |  |
|    | *  | 95/06731   | 03/09/95 | WO (Usman et al.)                  |  |  |  |  |
|    | *  | 95/11304   | 04/27/95 | WO (Usman et al.)                  |  |  |  |  |
|    | *  | 95/11910   | 05/04/95 | WO (Dudycz et al.)                 |  |  |  |  |
|    | *  | 96/10390   | 04/11/96 | WO (Ansell et al.)                 |  |  |  |  |
|    | *  | 96/10391   | 04/11/96 | WO (Choi et al.)                   |  |  |  |  |
|    | *  | 96/10392   | 04/11/96 | WO (Holland et al.)                |  |  |  |  |
|    | 1. | 96/18736 ✓ | 06/20/96 | WO (Beigelman et al.)              |  |  |  |  |
|    | *  | 96/22689   | 08/01/96 | WO (Pyle et al.)                   |  |  |  |  |
|    | *  | 97/26270   | 07/24/97 | WO (Beigelman et al.)              |  |  |  |  |
|    | *  | 98/27104   | 06/25/98 | WO (Breaker et al.)                |  |  |  |  |
|    | *  | 98/28317   | 07/02/98 | WO (Matulic-Adamic et al.)         |  |  |  |  |
|    | *  | 98/43993   | 10/08/98 | WO (Breaker et al.)                |  |  |  |  |
|    | *  | 98/58058   | 12/23/98 | WO (Ludwig & Sproat)               |  |  |  |  |
|    | *  | 98/13526   | 04/02/98 | WO (Woolf et al.)                  |  |  |  |  |
|    | *  | 99/04819   | 02/04/99 | WO (Klimuk)                        |  |  |  |  |
|    | *  | 99/05094   | 02/04/99 | WO (Beigelman et al.)              |  |  |  |  |
|    | *  | 99/07409   | 02/18/99 | WO (Deschamps de Paillette et al.) |  |  |  |  |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|  |  |  |                                     |
|--|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)                            | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b> |  | <b>Applicant:</b>                                  |                                     |
| (Use several sheets if necessary)                              |  | James McSwiggen                                    |                                     |
|  |  | <b>Filing Date:</b>                                | <b>Group:</b>                       |
|  |  | February 20, 2004                                  |                                     |

|    |   |          |          |                           |  |  |  |  |
|----|---|----------|----------|---------------------------|--|--|--|--|
| 86 | * | 99/14226 | 03/25/99 | WO (Wengel et al.)        |  |  |  |  |
|    | * | 99/16871 | 04/08/99 | WO (Eckstein et al.)      |  |  |  |  |
|    | * | 99/17120 | 04/08/99 | WO (Davis and Bishop)     |  |  |  |  |
|    | * | 99/29842 | 06/17/99 | WO (Sullenger et al.)     |  |  |  |  |
|    | * | 99/31262 | 06/24/99 | WO (Barry et al.)         |  |  |  |  |
|    | * | 99/32619 | 07/01/99 | WO (Fire et al.)          |  |  |  |  |
|    | * | 99/49029 | 09/30/99 | WO (Graham et al.)        |  |  |  |  |
|    | * | 99/53050 | 10/21/99 | WO (Waterhouse et al.)    |  |  |  |  |
|    | * | 99/54459 | 10/28/99 | WO (Thompson et al.)      |  |  |  |  |
|    | * | 99/55857 | 11/04/99 | WO (Beigelman et al.)     |  |  |  |  |
|    | * | 99/61631 | 12/02/99 | WO (Heifetz et al.)       |  |  |  |  |
|    | * | 99/66063 | 12/23/99 | WO (Manoharan et al.)     |  |  |  |  |
|    | * | 00/01846 | 01/13/00 | WO (Plaetinck et al.)     |  |  |  |  |
|    | * | 00/17369 | 03/30/00 | WO (Gurney et al.)        |  |  |  |  |
|    | * | 00/24931 | 05/04/00 | WO (Nathan and Ellington) |  |  |  |  |
|    | * | 00/26226 | 05/11/00 | WO (Breaker et al.)       |  |  |  |  |
|    | * | 00/44895 | 08/03/00 | WO (Kreutzer et al.)      |  |  |  |  |
|    | * | 00/44914 | 08/03/00 | WO (Li et al.)            |  |  |  |  |
| ✓  | * | 00/49035 | 08/24/00 | WO (Sheen)                |  |  |  |  |

|   |                        |
|---|------------------------|
| <b>EXAMINER</b>   | <b>DATE CONSIDERED</b> |
|  | 8/3/05                 |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-105  
(400/146)

Serial No.

10/783,128

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

James McSwiggen

Filing Date:

February 20, 2004

Group:

|    |   |          |          |                            |  |  |  |  |
|----|---|----------|----------|----------------------------|--|--|--|--|
| kl | * | 00/53722 | 09/14/00 | WO (O'Hare and Normand)    |  |  |  |  |
|    | * | 00/63364 | 10/26/00 | WO (Pachuk et al.)         |  |  |  |  |
|    | * | 00/66604 | 11/09/00 | WO (Wengel et al.)         |  |  |  |  |
|    | * | 01/04313 | 01/18/01 | WO (Satishchandran et al.) |  |  |  |  |
|    | * | 01/29058 | 04/26/01 | WO (Mello et al.)          |  |  |  |  |
|    | * | 01/36646 | 05/25/01 | WO (Zernicka-Goetz et al.) |  |  |  |  |
|    | * | 01/38551 | 05/31/01 | WO (Grossniklaus)          |  |  |  |  |
|    | * | 01/42443 | 06/14/01 | WO (Churikov et al.)       |  |  |  |  |
|    | * | 01/49844 | 07/12/01 | WO (Driscoll et al.)       |  |  |  |  |
|    | * | 01/53475 | 07/26/01 | WO (Cogoni et al.)         |  |  |  |  |
|    | * | 01/68836 | 09/20/01 | WO (Beach et al.)          |  |  |  |  |
|    | * | 01/70944 | 09/27/01 | WO (Honer et al.)          |  |  |  |  |
|    | * | 01/70949 | 09/27/01 | WO (Graham et al.)         |  |  |  |  |
|    | * | 01/72774 | 10/04/01 | WO (Deak et al.)           |  |  |  |  |
|    | * | 01/75164 | 10/11/01 | WO (Tuschl et al.)         |  |  |  |  |
|    | * | 01/92513 | 12/06/01 | WO (Arndt et al.)          |  |  |  |  |
|    | * | 01/96584 | 12/20/01 | WO (Mushegian et al.)      |  |  |  |  |
|    | * | 02/15876 | 02/28/02 | WO (Beigelman et al.)      |  |  |  |  |
| ✓  | * | 02/22636 | 03/21/02 | WO (Bennett et al.)        |  |  |  |  |

EXAMINER

DATE CONSIDERED

8/3/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|                                     |  |  |                                     |
|-------------------------------------|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32) | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
|                                     |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|                                     |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

|    |   |                               |          |                       |  |  |  |  |
|----|---|-------------------------------|----------|-----------------------|--|--|--|--|
| KC | * | 02/38805                      | 05/16/02 | WO (Echeverri et al.) |  |  |  |  |
|    | * | 02/44321                      | 06/06/02 | WO (Tuschl et al.)    |  |  |  |  |
|    | * | 02/55692                      | 07/18/02 | WO (Kreutzer et al.)  |  |  |  |  |
|    | * | 02/55693                      | 07/18/02 | WO (Kreutzer et al.)  |  |  |  |  |
|    | * | 02/094185<br>(PCT/US02/15876) | 11/28/02 | WO (Beigelman et al.) |  |  |  |  |
|    | * | 03/024420                     | 03/27/03 | WO (Ahlheim et al.)   |  |  |  |  |
|    | * | 03/046185                     | 06/05/03 | WO (Wang et al.)      |  |  |  |  |
|    | * | 03/047518                     | 06/12/03 | WO (Wang et al.)      |  |  |  |  |
|    | * | 03/064625                     | 08/07/03 | WO (Woolf et al.)     |  |  |  |  |
|    | * | 03/064626                     | 08/07/03 | WO (Woolf et al.)     |  |  |  |  |
|    | * | 03/070918<br>(PCT/US03/05346) | 08/28/03 | WO (McSwiggen et al.) |  |  |  |  |
|    | * | 03/074654<br>(PCT/US03/05028) | 09/12/03 | WO (McSwiggen et al.) |  |  |  |  |
| ✓  | * | 04/013280                     | 02/12/04 | WO (Davidson et al.)  |  |  |  |  |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


|    |   |  |
|----|---|--|
| KC | * | Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <i>Science</i> 271:1410-1413 (1996)                  |
| ✓  | * | Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001) |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |  |  |
|----|--|--|
| KC |  | * Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)  |
|    |  | * Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998) |
|    |  | * Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <i>Science</i> 297:1818-1819 (2002)   |
|    |  | * Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Research</i> 19:2499 (1991)   |
|    |  | * Antopolsky et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," <i>Bioconjugate Chem.</i> 10:598-606 (1999)  |
|    |  | * Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <i>Science</i> 279:377-380 (1998)   |
|    |  | * Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980)  |
|    |  | * Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)   |
|    |  | * Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <i>Biochemistry</i> 34:6504-6512 (1995)   |
| ✓  |  | * Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998)  |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |  |
|----|--|
| KC | * Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <u>Brain Research Protocols</u> 3:83-87 (1998)                                  |
|    | * Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," <u>Science</u> 261:1411-1418 (1993)  |
|    | * Basi et al., "Antagonistic Effects of $\beta$ -Site Amyloid Precursor Protein-cleaving Enzymes 1 and 2 on $\beta$ -Amyloid Peptide Production in Cells*," <u>The Journal of Biological Chemistry</u> , 278, 31512-31520 (2003) |
|    | * Bass, "Double-Stranded RNA as a Template for Gene Silencing," <u>Cell</u> , 101, 235-238 (2000)  |
|    | * Bass, "The short answer," <u>Nature</u> 411:428-429 (2001)   |
|    | * Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <u>Tetrahedron</u> 49:1925-1963 (1993)   |
|    | * Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," <u>Science</u> 257:635-641 (1992)  |
|    | * Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>The Journal of Biological Chemistry</u> 270:25702-25708 (1995)   |
|    | * Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <u>Nucleosides &amp; Nucleotides</u> 16:951-954 (1997)  |
|    | * Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <u>Bioconjugate Chem.</u> 8:204-212 (1997)  |
|    | * Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <u>Nature</u> 409:363-366 (2001)   |
|    | * Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <u>EBMO J.</u> 12:2567-2574 (1993)   |
| ↓  | * Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <u>Genes &amp; Development</u> 6:129-134 (1992)   |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |   |  |
|----|---|--|
| KC | * | Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)                   |
|    | * | Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the Tetrahymena Ribozyme," <i>Biochemistry</i> 35:648-568 (1996)  |
|    | * | Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)          |
|    | * | Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)   |
|    | * | Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," <i>Nucleic Acids Research</i> 22:4681-4688 (1994)                               |
|    | * | Bonora et al., "Biological Properties of Antisense Oligonucleotides Conjugated to Different High-Molecular Mass Poly(ethylen glycols)," <i>Nucleosides &amp; Nucleotides</i> 18:1723-1725 (1999) |
|    | * | Bonora et al., "Synthesis and Characterization of High-Molecular Mass Polyethylene Glycol-Conjugated Oligonucleotides," <i>Bioconjugate Chem.</i> 8:793-797 (1997)                               |
|    | * | Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)   |
|    | * | Breaker et al., "A DNA enzyme with Mg <sup>2+</sup> -dependent RNA phosphoesterase activity," <i>Chemistry &amp; Biology</i> 2(10):655-660 (1995)  |
|    | * | Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)  |
| ✓  | * | Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)  |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |  |   |
|----|--|---|
| KC |  | * Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998) |
|    |  | * Broadus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>Neurosurg. Focus</i> 3(5):Article 4 (1997)     |
|    |  | * Broadus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>J Neurosurg</i> 88:734-742 (1998)              |
|    |  | * Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)   |
|    |  | * Buckwold et al., "Effects of a Naturally Occurring Mutation in the Hepatitis B Virus Basal Core Promoter on Precore Gene Expression and Viral Replication," <i>Journal of Virology</i> , 5845-5851 (1996)                 |
|    |  | * Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <i>Cornea</i> 4:35-41 (1985/1986)  |
|    |  | * Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)  |
|    |  | * Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic &amp; Medicinal Chemistry</i> 5:1999-2010 (1997)   |
|    |  | * Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)  |
|    |  | * Cebon et al., "New DNA Modification Strategies Involving Oxime Formation," <i>Aust. J. Chem.</i> 53:333-339 (2000)  |
|    |  | * Cech, "Ribozymes and Their Medical Implications," <i>JAMA</i> 260:3030-3034 (1988)  |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|   |    |   |
|---|----|---|
| K | *  | Chaloin et al., "Design of Carrier Peptide-Oligonucleotide Conjugates With Rapid Membrane Translocation and Nuclear Localization Properties," <i>BBRC</i> 243:601-608 (1998)  |
|   | *  | Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <i>Nucleic Acids Research</i> 23(20):4092-4096 (1995)   |
|   | 2. | Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992)   |
|   | *  | Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> , 9:1034-1048 (2003)  |
|   | *  | Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector <i>in vitro</i> ," <i>Bull. Korean Chem. Soc.</i> , 22, 46-52 (2001)   |
|   | 3. | Chowrira et al., " <i>In Vitro</i> and <i>in Vivo</i> Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <i>J. Biol. Chem.</i> 269:25856-25864 (1994)  |
|   | *  | Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <i>Nature</i> 354:320-322 (1991)  |
|   | *  | Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," <i>Neuroscience Letters</i> 257:135-138 (1998) |
|   | *  | Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)  |
|   | *  | Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)   |
| ✓ | *  | Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From <i>Neurospora</i> VS RNA," <i>Biochemistry</i> 32:2795-2799 (1993)   |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |    |   |
|----|----|---|
| KC | *  | Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)   |
|    | *  | Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal <i>versus</i> Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999) |
|    | 4. | Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)   |
|    | *  | Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)  |
|    | *  | Crooke, "Antisense Therapeutics," <i>Biotechnology and Genetic Engineering Reviews</i> 15:121-157 (1998)  |
|    | *  | Crooke, "Progress in Antisense Technology: The End of the Beginning," <i>Methods in Enzymology</i> 313:3-45 (1999)  |
|    | *  | d'Aldin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission in vivo," <i>Molecular Brain Research</i> 55:151-164 (1998)  |
|    | *  | Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of in Vitro Reaction Rates and Products," <i>J. Mol. Biol.</i> 256:31-49 (1996)  |
|    | *  | Defrancq and Lhomme, "Use of an Aminooxy Linker for the Functionalization of Oligodeoxyribonucleotides," <i>Bioorganic &amp; Medicinal Chem. Lett.</i> 11:931-933 (2001)  |
|    | *  | Delihas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <i>Nature Biotechnology</i> 15:751-753 (1997)   |
|    | *  | Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999)   |
| ✓  | 5. | Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)  |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |   |
|----|---|
| ke | * Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," <i>Journal of Endocrinology</i> 157:169-175 (1998) |
|    | * Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]   |
|    | * Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992)  |
|    | * Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)  |
|    | * Edbauer et al., Resenilin and nicastrin regulate each other and determine amyloid $\beta$ -peptide production via complex formation," <i>PNAS</i> , 99, 8666-8671 (2002)  |
|    | * Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> 365:566-568 (1993)   |
|    | * Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)  |
|    | * Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)   |
|    | * Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)   |
| ↓  | * Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)   |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |    |  |
|----|----|--|
| KC | 6. | Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)   |
|    | *  | Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)   |
|    | *  | Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and <i>In Vivo</i> , Using $\beta$ -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <u>Antisense and Nucleic Acid Drug Dev.</u> 10:469-478 (2000)                      |
|    | *  | Erbacher et al., "Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <u>The Journal of Gene Medicine</u> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18] |
|    | *  | Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," <u>Gene</u> 82:53-61 (1989)   |
|    | *  | Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)  |
|    | *  | Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <u>Biochimica et Biophysica Acta</u> 1329:345-356 (1997)  |
|    | *  | Findeis, "Stepwise Synthesis of a GalNAc-containing Cluster Glycoside Ligand of the Asialoglycoprotein Receptor," <u>Int. J. Peptide Protein Res.</u> 43:477-485 (1994)  |
|    | *  | Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <u>Nature</u> 391:806-811(1998)  |
|    | *  | Fire, "RNA-triggered Gene Silencing," <u>TIG</u> 15:358-363(1999)  |
|    | *  | Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)  |
| ✓  | *  | Fox, "Targeting DNA with Triplexes," <u>Current Medicinal Chemistry</u> 7:17-37 (2000)   |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |     |  |
|----|-----|--|
| KE | *   | Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]                   |
|    | *   | Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003)  |
|    | *   | Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)                               |
|    | 7.  | Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993) |
|    | 8.  | GenBank Accession No. AB016794   |
|    | *   | GenBank Accession No. AB020693   |
|    | 9.  | GenBank Accession No. AB035726   |
|    | 10. | GenBank Accession No. AB035727   |
|    | 11. | GenBank Accession No. AB038653   |
|    | 12. | GenBank Accession No. AB050194   |
|    | 13. | GenBank Accession No. AC005516   |
|    | 14. | GenBank Accession No. AC006512   |
|    | 15. | GenBank Accession No. AF004883   |
|    | 16. | GenBank Accession No. AF004884   |
|    | 17. | GenBank Accession No. AF020275   |
|    | 18. | GenBank Accession No. AF032103   |
|    | 19. | GenBank Accession No. AF032105   |
|    | *   | GenBank Accession No. AF037412   |
|    | *   | GenBank Accession No. AF063658   |
|    | *   | Genbank Accession No. AF100308.1   |
| ✓  | 20. | GenBank Accession No. AJ000501   |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-105  
(400/146)

Serial No.

10/783,128

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

James McSwiggen

Filing Date:

February 20, 2004

Group:

|     |                                |
|-----|--------------------------------|
| 21. | GenBank Accession No. AJ000517 |
| *   | GenBank Accession No. AJ430458 |
| 22. | GenBank Accession No. AK056192 |
| 23. | GenBank Accession No. AK095017 |
| 24. | GenBank Accession No. AK125125 |
| 25. | GenBank Accession No. AL009031 |
| 26. | GenBank Accession No. AL390059 |
| 27. | GenBank Accession No. BC022245 |
| 28. | GenBank Accession No. BC031790 |
| 29. | GenBank Accession No. BC033711 |
| 30. | GenBank Accession No. BC047894 |
| 31. | GenBank Accession No. BC051795 |
| *   | GenBank Accession No. D00239   |
| *   | GenBank Accession No. D11168   |
| 32. | GenBank Accession No. D31840   |
| 33. | GenBank Accession No. D38529   |
| *   | GenBank Accession No. D50483.1 |
| *   | GenBank Accession No. K02121   |
| 34. | GenBank Accession No. L12392   |
| 35. | GenBank Accession No. L20431   |
| *   | GenBank Accession No. L24917   |
| *   | GenBank Accession No. L38318   |
| *   | GenBank Accession No. M16248   |
| 36. | GenBank Accession No. M20132   |
| 37. | GenBank Accession No. M21748   |
| *   | GenBank Accession No. M31724   |


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|     |                                   |
|-----|-----------------------------------|
| 38. | GenBank Accession No. M64930      |
| 39. | GenBank Accession No. M73069      |
| *   | GenBank Accession No. NC 001345   |
| *   | GenBank Accession No. NC 001347   |
| *   | GenBank Accession No. NC 001353   |
| *   | GenBank Accession No. NC 001563   |
| *   | GenBank Accession No. NC 001781   |
| 40. | GenBank Accession No. NM 000044   |
| 41. | GenBank Accession No. NM 000068   |
| 42. | GenBank Accession No. NM 000332   |
| 43. | GenBank Accession No. NM 000333   |
| *   | GenBank Accession No. NM 001285   |
| 44. | GenBank Accession No. NM 001940   |
| *   | GenBank Accession No. NM 001982   |
| 45. | GenBank Accession No. NM 002111   |
| *   | GenBank Accession No. NM 002592.1 |
| *   | GenBank Accession No. NM 002667   |
| *   | GenBank Accession No. NM 002737   |
| 46. | GenBank Accession No. NM 002973   |
| *   | GenBank Accession No. NM 003219   |
| *   | Genbank Accession No. NM 003376.1 |
| *   | GenBank Accession No. NM 004283   |
| *   | GenBank Accession No. NM 004448   |
| 47. | GenBank Accession No. NM 004576   |
| 48. | GenBank Accession No. NM 004993   |
| *   | GenBank Accession No. NM 005228   |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-105  
(400/146)

Serial No.

10/783,128

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

James McSwiggen

Filing Date:

February 20, 2004

Group:

|           |     |                                 |
|-----------|-----|---------------------------------|
| <i>lc</i> | *   | GenBank Accession No. NM_005235 |
|           | 49. | GenBank Accession No. NM_023035 |
|           | 50. | GenBank Accession No. NM_030660 |
|           | 51. | GenBank Accession No. NM_181674 |
|           | 52. | GenBank Accession No. NM_181675 |
|           | 53. | GenBank Accession No. S64648    |
|           | 54. | GenBank Accession No. S75313    |
|           | *   | GenBank Accession No. S82227    |
|           | 55. | GenBank Accession No. U06702    |
|           | 56. | GenBank Accession No. U23851    |
|           | *   | GenBank Accession No. U51188    |
|           | 57. | GenBank Accession No. U64820    |
|           | 58. | GenBank Accession No. U64821    |
|           | 59. | GenBank Accession No. U64822    |
|           | 60. | GenBank Accession No. U70323    |
|           | 61. | GenBank Accession No. U79666    |
|           | *   | GenBank Accession No. U86046    |
|           | *   | GenBank Accession No. X01087    |
|           | *   | GenBank Accession No. X02316    |
|           | *   | GenBank Accession No. X07203    |
|           | *   | GenBank Accession No. X60667    |
|           | 62. | GenBank Accession No. X79204    |
|           | 63. | GenBank Accession No. X99897    |
|           | *   | GenBank Accession No. XM_015620 |
|           | *   | GenBank Accession No. XM_033884 |
| <i>✓</i>  | *   | GenBank Accession No. XM_067723 |

EXAMINER


DATE CONSIDERED

8/3/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |     |  |
|----|-----|--|
| KE | 64. | GenBank Accession No. Y08262   |
|    | 65. | GenBank Accession No. Z69837   |
|    | *   | Ghirnikar et al., "Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides," <i>Neuroscience Letters</i> 247:21-24 (1998)  |
|    | *   | Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)   |
|    | *   | Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)   |
|    | *   | Godwin et al., "The Synthesis of Biologically Active Pteroyl oligo-γ-L-Glutamates (Folic Acid Conjugates)," <i>The Journal of Biological Chemistry</i> 247:2266-2271 (1972)                                |
|    | *   | Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)  |
|    | *   | Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <i>Neuroscience</i> 76:1153-1158 (1997)  |
|    | *   | Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <i>Bioconjugate Chem.</i> , 10, 1068-1074 (1999)   |
|    | 66. | Good et al., "Expression of small, therapeutic RNAs in human nuclei," <i>Gene Therapy</i> 4:45-54 (1997)   |
|    | *   | Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," <i>Diabetologia</i> 36:282-291 (1993)       |
|    | *   | Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <i>Biochemistry</i> 34:4068-4076 (1995)                                    |
|    | *   | Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <i>Chemistry &amp; Biology</i> 2:761-770 (1995) |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |     |  |
|----|-----|--|
| KE | 67. | Groothuis and Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," <i>Journal of NeuroVirology</i> 3:387-400 (1997)  |
|    | *   | Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," <i>Cell</i> 35:849-857 (1983)   |
|    | *   | Guo and Collins, "Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <i>EMBO J.</i> 14:368-376 (1995)   |
|    | *   | Habus et al., "A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates," <i>Bioconjugate Chem.</i> 9:283-291 (1998)   |
|    | *   | Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <i>Science</i> 297:2232-2237 (2002)  |
|    | *   | Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999)   |
|    | *   | Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <i>Antisense &amp; Nucleic Acid Drug Development</i> 9:25-31 (1999)   |
|    | *   | Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)   |
|    | *   | Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)STRSV Sequence," <i>Biochemistry</i> 28:4929-4933 (1989)   |
|    | *   | Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <i>Nucleic Acids Research</i> 18:299-304 (1990)   |
|    | *   | Haniu et al., "Characterization of Alzheimer's $\beta$ -Secretase Protein BACE," <i>The Journal of Biological Chemistry</i> , 275, 21099-21106 (2000)  |
| J  | *   | Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003) |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |  |
|----|--|
| KC | * Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," RNA 1:210-218 (1995)  |
|    | * Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 285:920-928 (1998)          |
|    | * Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," Gene 82:43-52 (1989)  |
|    | * Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," Biochemistry 34:15813-15828 (1995)  |
|    | * Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," Science 287:820-825 (2000)   |
|    | * Herschlag and Cech, "Catalysis of RNA Cleavage by the Tetrahymena thermophila Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," Biochemistry 29:10159-10171 (1990)          |
|    | * Herschlag and Cech, "Catalysis of RNA Cleavage by the Tetrahymena thermophila Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," Biochemistry 29:10172-10180 (1990) |
|    | * Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," Biochemistry 33:3374-3385 (1994)  |
|    | * Hertel et al., "Numbering System for the Hammerhead," Nucleic Acids Research 20:3252 (1992)  |
|    | 68. Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," <i>Current Opinion in Molecular Therapeutics</i> 1:336-343 (1999)  |
|    | * Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <i>Handbook of Exp. Pharmacol.</i> 137:165-192 (1999)  |
| ↓  | * Hudson et al., "Cellular Delivery of Hammerhead Ribozymes Conjugated to a Transferrin Receptor Antibody," Int'l Jour. of Pharmaceutics 182:49-58 (1999)  |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |     |   |
|----|-----|---|
| ke | *   | Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," VCH, 331-417  |
|    | *   | Hussain et al., "Identification of a Novel Aspartic Protease (Asp 2) as $\beta$ -Secretase," <i>Molecular and Cellular Neuroscience</i> , 14, 419-427 (1999)  |
|    | *   | Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <i>Science</i> 297:2056-2060 (2002)  |
|    | *   | Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," <i>Science</i> 293:834-838 (2001)   |
|    | *   | International Search Report for PCT/US03/04710 mailed November 18, 2003   |
|    | *   | International Search Report for PCT/US03/05028 mailed October 17, 2003  |
|    | *   | International Search Report for PCT/US03/05346 mailed October 17, 2003  |
|    | *   | International Search Report mailed November 19, 2003 for PCT/US03/18911   |
|    | *   | Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <i>Chem. Pharm. Bull.</i> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet) |
|    | *   | Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <i>Biochemical and Biophysical Research Communication</i> 214(2):403-409 (1995)  |
|    | 69. | Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <i>Science</i> 229:345-352 (1985)   |
|    | *   | Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," <i>Journal of Biological Chemistry</i> 271:29107-29112 (1996)   |
|    | *   | Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <i>Tetrahedron Letters</i> 34:301-304 (1993) (sometimes mistakenly referred to as Jscke)  |
| J  | *   | Jaschke et al., "Synthesis and Properties of Oligodeoxyribonucleotide-polyethylene Glycol Conjugates," <i>Nucleic Acids Research</i> 22:4810-4817 (1994)  |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                   |
|---|--|--|-------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b>                      | <b>Serial No.</b> |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | 04-105<br>(400/146)                          | 10/783,128        |
|   |  | <b>Applicant:</b><br><br>James McSwiggen     |                   |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004 | <b>Group:</b>     |


|    |     |   |
|----|-----|---|
| KC |     | * Jaschke, "Oligonucleotide-Poly(ethylene glycol) Conjugates: Synthesis, Properties, and Application," American Chemical Society 680:265-283 (1997)   |
|    |     | * Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <i>Clinical Chemistry</i> 45:1628-1650 (1999)  |
|    |     | * Jenuwein, "An RNA-Guided Pathway for the Epigenome," <i>Science</i> 297:2215-2218 (2002)  |
|    |     | * Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <i>Fundam. Clin. Pharmacol.</i> 13:16-26 (1999)  |
|    |     | * Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <i>Genes &amp; Development</i> 7:130-138 (1993)  |
|    |     | * Joyce et al., "Amplification, mutation and selection of catalytic RNA," <i>Gene</i> 82:83-87 (1989)   |
|    |     | * Joyce, "Directed Molecular Evolution," <i>Scientific American</i> 267:90-97 (1992)  |
|    | 70. | Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA <sub>A</sub> Receptor $\gamma$ 2 Subunit," <i>Euro. Jour. Of Pharmacology</i> 340:153-160 (1997) |
|    |     | * Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <i>Tetrahedron Letters</i> 39:1131-1134 (1998)   |
|    | 71. | Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <i>Antisense Research &amp; Development</i> 2:3-15 (1992)  |
|    |     | * Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <i>Nature</i> 362:841-844 (1993)  |
|    |     | * Knitt et al., "ph Dependencies of the Tetrahymena Ribozyme Reveal an Unconventional Origin of an Apparent pKa," <i>Biochemistry</i> 35:1560-1570 (1996)   |
|    |     | * Koch et al., "Vascular Endothelial Growth Factor," <i>Journal of Immunology</i> , 152:4149-4156 (1994)  |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|  |  |  |                   |
|--|--|--|-------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b>                      | <b>Serial No.</b> |
| <p align="center"><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b></p> <p align="center">(Use several sheets if necessary)</p> |  | 04-105<br>(400/146)                          | 10/783,128        |
|  |  | <b>Applicant:</b><br><br>James McSwiggen     |                   |
|  |  | <b>Filing Date:</b><br><br>February 20, 2004 | <b>Group:</b>     |


|    |  |  |
|----|--|--|
| KC |  | * Koike et al., "Thimet Oligopeptidase Cleaves the Full-Length Alzheimer Amyloid Precursor Protein at a $\beta$ -Secretase Cleavage Site in COS Cells," <i>J. Biochem.</i> , 126, 235-242 (1999)                               |
|    |  | * Kõre, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule," <i>Nucleic Acids Research</i> , 26(18):4116-4120 (1998).  |
|    |  | * Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," <i>Blood</i> 91:852-862 (1998)                        |
|    |  | * Kumar and Ellington, "Artificial evolution and natural ribozymes," <i>FASEB J.</i> 9:1183-1195 (1995)  |
|    |  | * Kunath et al., "The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.," <i>Medline (Pharm Res.)</i> 19(6): 810-817 (6/1/2002) |
|    |  | * Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)   |
|    |  | * Kuwabara et al., "Allosterically Controllable Ribozymes with Biosensor Functions," <i>Current Opinion in Chem. Biol.</i> 4:669-677 (2000)  |
|    |  | * Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)  |
|    |  | * Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)  |
|    |  | * Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <i>ACS Symposium Series</i> 752:184-192 (2000)  |
|    |  | * Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <i>Glyconjugates J.</i> 4:317-328 (1987)      |
| J  |  | * Lee et al., "Enhancing the Catalytic Repertoire of Nucleic Acids: A Systematic Study of Linker Length and Rigidity," <i>Nucleic Acids Research</i> 29:1565-1573 (2001)   |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br>February 20, 2004       | <b>Group:</b>                   |

|    |     |  |
|----|-----|--|
| KC | 72. | Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," <i>Nature Biotechnology</i> 19:500-505 (2002)   |
|    | *   | Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)  |
|    | *   | Lendlein et al., "Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications," <i>Science</i> , 296, 1673-1676 (2002)  |
|    | *   | Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," <i>Journal of Ocular Pharmacology</i> 10:273-281 (1994)  |
|    | 73. | L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in $\alpha$ -Lactalbumin mRNA Levels in C1271 Mouse," <i>EMBO J.</i> 11:4411-4418 (1992)  |
|    | *   | Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage $\lambda$ burst size," <i>Nucleic Acids Research</i> 24:835-842 (1996)  |
|    | *   | Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the Tetrahymena Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <i>Biochemistry</i> 34:14394-14399 (1995) |
|    | *   | Lichner et al., "Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences," <i>Journal of General Virology</i> , 84, 975-980 (2003)  |
|    | 74. | Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Methods Enzymol.</i> 217:47-66 (1993)   |
|    | *   | Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)  |
| ↓  | *   | Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)   |


|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



|   |  |  |                   |
|---|--|--|-------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b>                      | <b>Serial No.</b> |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | 04-105<br>(400/146)                          | 10/783,128        |
|   |  | <b>Applicant:</b><br><br>James McSwiggen     |                   |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004 | <b>Group:</b>     |


|    |     |   |
|----|-----|---|
| ke | *   | Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)   |
|    | *   | Lin et al., "Human aspartic protease memapsin 2 cleaves the $\beta$ -secretase site of $\beta$ -amyloid precursor protein," <i>PNAS</i> , 97, 1456-1460 (2000)  |
|    | *   | Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)   |
|    | *   | Lindgren et al., "Translocation Properties of Novel Cell Penetrating Transporter and Penetratin Analogues," <i>Bioconjugate Chem.</i> 11:619-626 (2000)   |
|    | *   | Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <i>J. Mol. Biol.</i> 235:1206-1217 (1994)  |
|    | 75. | Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993) |
|    | *   | Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)  |
|    | *   | Liu et al., "Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA," <i>Gene Therapy</i> , 6, 1258-1266 (1999)  |
|    | *   | Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001)   |
|    | *   | Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <i>Proc. Natl. Acad. Sci. USA</i> 91:6977-6981 (1994)   |
|    | *   | Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," <i>Leukemia Research</i> 20:925-930 (1996)   |
| J  | *   | Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)  |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br>James McSwiggen           |                                 |
|   |  | <b>Filing Date:</b><br>February 20, 2004       | <b>Group:</b>                   |


|    |     |   |
|----|-----|---|
| KC |     | * Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993) |
|    |     | * Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," <i>Biochemistry</i> 29:8820-8826 (1990)  |
|    |     | * Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)   |
|    |     | * Matulic-Adamic et al., "Functionalized Nucleoside 5'-triphosphates for In Vitro Selection of New Catalytic Ribonucleic Acids," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 10:1299-1302 (2000)  |
|    |     | * Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)   |
|    |     | * McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides &amp; Nucleotides</i> 10:287-290 (1991)  |
|    | 76. | McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:399-403 (1986)  |
|    |     | * McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <i>RNA</i> 2:395-403 (1996)  |
|    | 77. | McLaughlin et al., "CAG Trinucleotide RNA Repeats Interact with RNA-Binding Proteins," <i>Am. J. Hum. Genet.</i> , 59:561-569 (1996)  |
|    |     | * McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <i>RNA</i> 8:842-850 (2002)   |
|    |     | * Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," <i>American Chemical Society</i> , pp. 24-39 (1994)   |
|    |     | * Michel and Westhof, "Slippery substrates," <i>Nat. Struct. Biol.</i> 1:5-7 (1994)   |
| ↓  |     | * Michel et al., "Structure and Activities of Group II Introns," <i>Annu. Rev. Biochem.</i> 64:435-461 (1995)   |

|  |                                |
|--|--------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/30/05 |
|--|--------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.











|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004   | <b>Group:</b>                   |


|    |     |  |
|----|-----|--|
| KC | *   | Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995) |
|    | 78. | Miller et al., "Allele-specific silencing of dominant disease genes," <u>PNAS</u> , 100:12, 7195-7200 (2003)   |
|    | *   | Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <u>Nature Biotechnology</u> 15:537-541 (1997)   |
|    | 79. | Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," <u>Nature Biotechnology</u> 19:497-500 (2002)  |
|    | *   | Mohr et al., "A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the Tetrahymena ribozyme," <u>Nature</u> 370:147-150 (1994)  |
|    | *   | Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)   |
|    | *   | Mori et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization," <u>Journal of Cellular Physiology</u> , 118(2) 253-263 (2001)  |
|    | *   | Morris et al., "A New Peptide Vector for Efficient Delivery of Oligonucleotides into Mammalian Cells," <u>Nucleic Acids Research</u> 25:2730-2736 (1997)   |
|    | 80. | Myers et al., "Factors Related to Onset Age of Huntington Disease," <u>Am. J. Hum. Genet.</u> , 34:481-488 (1982)  |
|    | *   | Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <u>Biochemistry</u> 33:1271-1277 (1994)   |
| ✓  | *   | Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <u>Ann. Rev. Biochem.</u> 44:273-293 (1975)   |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br>February 20, 2004       | <b>Group:</b>                   |


|   |   |
|---|---|
|    | * Nomura et al., "Development of an Efficient Intermediate, $\alpha$ -[2-(Trimethylsilyl) ethoxy]-2-N-[2-trimethylsilyl]ethoxycarbonyl]folic Acid, for the Synthesis of Folate ( $\gamma$ )-Conjugates, and Its Application to the Synthesis of Folate-Nucleoside Conjugates," <i>J. Org. Chem.</i> 65:5016-5021 (2000) |
|    | 81. Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <i>Nucleic Acids Research</i> 22(14):2830-2836 (1994)  |
|   | * Noviello et al., "Autosomal Recessive Hypercholesterolemia Protein Interacts with and Regulates the Cell Surface Level of Alzheimer's Amyloid $\beta$ Precursor Protein*," <i>The Journal of Biological Chemistry</i> , 278, 31843-31847 (2003)   |
|  | 82. Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <i>Nature Medicine</i> 8:7, 681-686 (2002)   |
|  | * Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> 107:309-321 (2001)  |
|  | 83. Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992)   |
|  | * Ohno-Matsui et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Am. J. Pathology</i> , 160, 711-719 (2002)  |
|  | 84. Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992)  |
|  | * Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)  |
|  | * Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)   |

|  |                               |
|--|-------------------------------|
| <b>EXAMINER</b><br> | <b>DATE CONSIDERED</b> 8/3/05 |
|--|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                   |
|---|--|--|-------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b>                      | <b>Serial No.</b> |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | 04-105<br>(400/146)                          | 10/783,128        |
|   |  | <b>Applicant:</b><br><br>James McSwiggen     |                   |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004 | <b>Group:</b>     |

|    |     |  |
|----|-----|--|
| KC |     | * O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994)  |
|    |     | * Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 ( <a href="http://www.pharmsci.org">http://www.pharmsci.org</a> ) p. 1- 11 (2001) |
|    |     | * Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990)   |
|    |     | * Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localizatin in Drosophila Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)   |
|    |     | * Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," <i>Proc. Natl. Acad. Sci. USA</i> 92:12510-12514 (1995)   |
|    |     | * Pandey et al., "Role ov B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- $\alpha$ -Induced Angiogenesis," <i>Science</i> 268:567-569 (1995)   |
|    |     | * Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)   |
|    |     | * Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)   |
|    |     | * Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> 67:519-528 (1992)   |
|    | 85. | Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nature Biotechnology</i> 20:505-508 (2002)   |
| v  |     | * Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)   |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |

|    |  |
|----|--|
| KC | * Perrotta and Been, "A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA," <i>Nature</i> 350:434-436 (1991)   |
|    | * Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis $\delta$ Virus RNA Sequence," <i>Biochemistry</i> 31:16-21 (1992)  |
|    | * Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System," <i>Bioconjugate Chem.</i> , 13, 845-854 (2002) |
|    | * Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)  |
|    | * Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci. USA</i> 92:905-909 (1995)  |
|    | * Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> 78:55-113 (1998)  |
|    | * Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)   |
|    | * Praseuth et al., "Triple helix formation and the antigen for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)   |
|    | * Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <i>Nucleic Acids Research</i> 21:4253-4258 (1993)  |
|    | * Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <i>Biochemistry</i> 33:2716-2725 (1994)  |
| ✓  | * Rajakumar et al., "Effects of Intrastriatal Infusion of D <sub>2</sub> Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997)   |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004   | <b>Group:</b>                   |

|    |     |   |
|----|-----|---|
| KC | *   | Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," <i>PNAS</i> , 100, 235-240 (2003)   |
|    | 86. | Reddy et al., "Behavioral abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length <i>HD</i> cDNA," <i>Nature Genetics</i> , 20, 198-202 (1998)                       |
|    | *   | Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <i>Science</i> 297:1831 (2002)   |
|    | *   | Reinhart et al., "MicroRNAs in Plants," <i>Genes &amp; Development</i> 16:1616-1626 (2002)  |
|    | 87. | Revilla et al., <i>Huntington Disease</i> , eMedicine.com, Inc. (2004)  |
|    | 88. | Reynolds et al., "Rational siRNA design for RNA interference," <i>Nature Biotechnology</i> , 22, 3, 326-330 (2004)  |
|    | *   | Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)  |
|    | *   | Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Ribonuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," <i>J. Biol. Chem.</i> 247:5243-5251 (1972) |
|    | *   | Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <i>Aids Research and Human Retroviruses</i> 8:183-189 (1992)  |
|    | *   | Ruoslahti, "RGD and Other Recognition Sequences for Integrins," <i>Annu. Rev. Cell Dev. Biol.</i> 12:697-715 (1996)   |
|    | 89. | Ryu et al., "Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease," <i>Experimental Neurology</i> , 183, 700-704 (2003)   |
|    | *   | Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <i>Principles of Nucleic Acid Structure</i> 158-200 (1984)                        |
| ↓  | *   | Salo et al., "Aminoxy Functionalized Oligonucleotides: Preparation, On-Support Derivatization, and Postsynthetic Attachment to Polymer Support," <i>Bioconjugate Chem.</i> 10:815-823 (1999)                |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br>February 20, 2004       | <b>Group:</b>                   |

|    |     |   |
|----|-----|---|
| KC | *   | Sanghvi et al., "Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer and Cheaper Activator," <u>Organic Process Res. &amp; Dev.</u> 4:175-181 (2000)   |
|    | *   | Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)   |
|    | *   | Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," <u>Biochemistry</u> 37:13330-13342 (1998)  |
|    | *   | Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <u>J. Am. Chem. Soc.</u> 122:2433-2439 (2000)  |
|    | 90. | Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)   |
|    | *   | Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In Neurospora Mitochondria," <u>Cell</u> 61:685-696 (1990)  |
|    | *   | Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a Neurospora Mitochondrial Plasmid Transcript," <u>Proc. Natl. Acad. Sci. USA</u> 88:8826-8830 (1991)  |
|    | 91. | Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)  |
|    | *   | Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using $\beta$ -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)                                 |
|    | *   | Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <u>The Journal of Biological Chemistry</u> 274:21783-21789 (1999)   |
|    | *   | Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <u>Nucleic Acids Research</u> 24:573-581 (1996) |


|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br><b>(Rev. 2-32)</b>  | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE</b><br><b>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |     |  |
|----|-----|--|
| KC | *   | Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as <i>Prog Neuropsychopharmacol Biol Psychiatry</i> 23:941-949, 1999] |
|    | *   | Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002)  |
|    | 92. | Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> , 115, 199-208 (2003)  |
|    | *   | Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," <i>Science</i> 285:1569-1572 (1999)   |
|    | *   | Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," <i>Cell</i> 81:991-1002 (1995)   |
|    | *   | Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <i>Nucleic Acids Research</i> 15:3113-3129 (1987)   |
|    | *   | Segarra et al., "Molecular characterization of the <i>Enterococcus faecalis</i> cytolsin activator," <i>Infection and Immunity</i> , 59, 4, 1239-1246 (1991) Database CAPLUS on STN, AN:1992:230597  |
|    | *   | Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)   |
|    | *   | Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)  |
|    | *   | Sharp et al., "RNAi and double-strand RNA," <i>Genes &amp; Development</i> , 13:139-141 (1999)   |
| ↓  | *   | Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003)   |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |     |  |
|----|-----|--|
| KC | *   | Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993)                |
|    | *   | Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)  |
|    | *   | Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)   |
|    | 93. | Sittler et al., "Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease," <i>Human Molecular Genetics</i> , 10:12, 1307-1315 (2001)                    |
|    | *   | Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense &amp; Nucleic Acid Drug Development</i> 8:75-85 (1998)        |
|    | *   | Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)  |
|    | *   | Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense &amp; Nucleic Acid Drug Development</i> 7:151-157 (1997)                              |
|    | *   | Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i> ]                    |
|    | *   | Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," <i>Science</i> 249:73-75 (1990)   |
| ↓  | *   | Strobel et al., "Exocyclic Amine of the Conserved G·U Pair at the Cleavage Site of the Tetrahymena Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <i>Biochemistry</i> 35:1201-1211 (1996) |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004   | <b>Group:</b>                   |


|    |     |   |
|----|-----|---|
| KC | *   | Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the Tetrahymena Ribozyme Reaction Site," <i>Science</i> 267:675-679 (1995)   |
|    | *   | Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <i>Nature</i> 371:619-622 (1994)   |
|    | 94. | Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)  |
|    | *   | Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <i>Cell</i> 63:601-608 (1990)  |
|    | *   | Sun, "Technology evaluation: SELEX, Gilead Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)   |
|    | *   | Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in <i>The RNA World</i> , edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)   |
|    | *   | Szostak, "In Vitro Genes," <i>TIBS</i> 17:89-93 (1993)  |
|    | 95. | Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991) |
|    | *   | Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <i>Cancer Research</i> 54:4233-4237 (1994)   |
|    | *   | Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <i>RNA</i> 3:914-925 (1997)   |
|    | 96. | The Huntington's Disease Collaborative Research Group, "A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes," <i>Cell</i> , 72, 971-983 (1993)   |
| ✓  | *   | Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <i>PNAS</i> , 99, 14640-14645 (2002)  |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004   | <b>Group:</b>                   |


|    |     |   |
|----|-----|---|
| KC | 97. | Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <u>Nucleic Acids Research</u> 23:2259-2268 (1995)   |
|    | *   | Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <u>Proc. Natl. Acad. Sci. USA</u> 90:1300-1304 (1993)   |
|    | *   | Turner et al., "Improved Parameters for Prediction of RNA Structure," <u>Cold Spring Harbor Symposia on Quantitative Biology</u> Volume LII, pp. 123-133 (1987)   |
|    | *   | Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)  |
|    | 98. | Turner, "Intrathecal drug delivery 2002," <u>Acta Neurochir</u> , [Supp.] 87:29-35 (2003)   |
|    | *   | Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <u>Molecular Interventions</u> , 295, 3, 158-167 (2002)   |
|    | *   | Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <u>Genes &amp; Development</u> 13:3191-3197 (1999)  |
|    | *   | Tuschl, "RNA Interference and Small Interfering RNAs," <u>Chembiochem</u> 2:239-245 (2001)  |
|    | *   | Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <u>Proc. Natl. Acad. Sci. USA</u> 96:7053-7058 (1999) |
|    | *   | Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <u>FEBS Letters</u> 421:280-284 (1998)  |
|    | *   | Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <u>Chemical Reviews</u> 90:544-584 (1990)  |
| ↓  | 99. | Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," <u>Nucleic Acids Research</u> , 32, 3, 936-948 (2004)   |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |


|    |      |  |
|----|------|--|
| KC |      | * Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)   |
|    |      | * Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987) |
|    |      | * Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)   |
|    |      | * Usman et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology</u> 1:527-533(1996)  |
|    |      | * Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)  |
|    | 100. | Van Dellen et al., "Genetic and environmental factors in the pathogenesis of Huntington's disease," <u>Neurogenetics</u> , 5:9-17 (2004)   |
|    |      | * Vassar et al., "β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <u>Science</u> 286:735-741 (1999)  |
|    | 101. | Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u> 21:3249-3255 (1993)   |
|    |      | * Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex," <u>Science</u> , 303, 672-676 (2004)  |
|    |      | * Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998)   |
|    |      | * Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <u>Science</u> 297:1833-1837 (2002)   |
| ✓  |      | * Wang et al., "Delivery of Antisense Oligodeoxyribonucleotides Against the Human Epidermal Growth Factor Receptor into Cultured KB Cells with Liposomes Conjugated to Folate via Polyethylene Glycol," <u>Proc. Natl. Acad. Sci. USA</u> 92:3318-3322 (1995)  |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|                                     |  |  |   |                                     |
|-------------------------------------|--|--|---|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32) | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> |  | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146)  | <b>Serial No.</b><br><br>10/783,128 |
|                                     |  |  | <b>Applicant:</b><br><br>James McSwiggen  |                                     |
|                                     |  |  | <b>Filing Date:</b><br><br>February 20, 2004  | <b>Group:</b>                       |
|                                     |  |  | <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |                                     |


|    |      |   |
|----|------|---|
| KC | *    | Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> , 95, 13959-13964 (1998)   |
|    | 102. | Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 <sup>+</sup> Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <i>Journal of Virology</i> 65:5531-5534 (1994) |
|    | *    | Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <i>Nucleic Acids Research</i> 23:2092-2096 (1995)  |
|    | *    | Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <i>Nature Cell Biology</i> 2:70-75 (2000)   |
|    | *    | Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <i>Nucleic Acids Research</i> 23(14):2677-2684 (1995)  |
|    | *    | Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <i>Methods in Molecular Biology</i> 74:59-69 (1997)   |
|    | 103. | Wood et al., "Protein aggregation in motor neurone disorders," <i>Neuropathology and Applied Neurobiology</i> , 29, 529-545 (2003)  |
|    | *    | Woolf et al., "Specificity of Antisense Oligonucleotides in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 89:7305-7309 (1992)  |
|    | *    | Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <i>The Journ. of Biol. Chem.</i> 262:4429-4432 (1987)   |
| ↓  | *    | Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," <i>BioPharm</i> 32-38 (1999)   |

|  |                        |
|--|------------------------|
| EXAMINER  | DATE CONSIDERED 8/3/05 |
|--|------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                 |
|---|--|--|---------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br>04-105<br>(400/146) | <b>Serial No.</b><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen       |                                 |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004   | <b>Group:</b>                   |


|    |      |  |
|----|------|--|
| KC | *    | Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," <i>Nature Biology</i> , Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003) |
|    | *    | Yan et al., "Membrane-anchored Aspartyl Protease with Alzheimer's Disease $\beta$ -Secretase Activity," <i>Nature</i> 402:533-537 (1999)   |
|    | *    | Yang et al., "Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection," <i>PNAS</i> , 99, 21, 13825-13830 (2002)   |
|    | 104. | Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 90:6340-6344 (1993)   |
|    | *    | Yuan et al., "Targeted cleavage of mRNA by human RNase P," <i>Proc. Natl. Acad. Sci. USA</i> 89:8006-8010 (1992)   |
|    | *    | Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <i>Cell</i> 101:25-33 (2000)   |
|    | *    | Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the Tetrahymena ribozyme," <i>Nucleic Acids Research</i> 24:854-858 (1996)  |
|    | 105. | Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <i>Mol. Cell. Biol.</i> 10:4529-4537 (1990)   |
|    | *    | Ziche et al., "Angiogenesis Can Be Stimulated or Repressed <i>In Vivo</i> by a Change in GM3:GD3 Ganglioside Ratio," <i>Laboratory Investigation</i> 67:711-715 (1992)   |
|    | *    | Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," <i>Cell</i> 83:529-538 (1995)   |
| ✓  | *    | Zinnen et al., "Chemically Modified siRNAa: Potential Anti-viral Hepatitis Therapeutics" (Abstract) March 2004   |

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

|   |  |  |                                     |
|---|--|--|-------------------------------------|
| <b>FORM PTO-1449</b><br>(Rev. 2-32)   | <b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b> | <b>Atty. Docket No.</b><br><br>04-105<br>(400/146) | <b>Serial No.</b><br><br>10/783,128 |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |  | <b>Applicant:</b><br><br>James McSwiggen           |                                     |
|   |  | <b>Filing Date:</b><br><br>February 20, 2004       | <b>Group:</b>                       |
|   |  |  |                                     |

|    |      |  |
|----|------|--|
| KC | 106. | Kwong et al., "RNAi-Mediated Inhibition of Mutated TTT in Huntingtons Disease Models," Program No. 208.18. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience (2003) Online. [ABSTRACT ONLY] |
|----|------|--|

|   |                               |
|---|-------------------------------|
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b> 8/3/05 |
|---|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.